Skip to main content
PatentCliff

Tecfidera Patent Protection

9 patents · Biogen Inc.

Reviewed by PatentCliff Editorial Team · Updated
C
Patent Strength
51/100
9
Total Patents
1
Assignees
2028
Earliest Expiration
2035
Latest Expiration

Patent Details

Patent #TitleAssigneeExpiresStatus
8399514Orange Book listed patentBiogen Inc.Feb 7, 20281.6y left
10391160Orange Book listed patentBiogen Inc.Mar 13, 20358.7y left
10555993Orange Book listed patentBiogen Inc.Mar 13, 20358.7y left
10994003Orange Book listed patentBiogen Inc.Mar 13, 20358.7y left
10959972Orange Book listed patentBiogen Inc.Nov 16, 20359.4y left
11129806Orange Book listed patentBiogen Inc.Nov 16, 20359.4y left
11007166Orange Book listed patentBiogen Inc.Nov 16, 20359.4y left
11007167Orange Book listed patentBiogen Inc.Nov 16, 20359.4y left
11246850Orange Book listed patentBiogen Inc.Nov 16, 20359.4y left

For Tecfidera, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Tecfidera is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.